BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.…
BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring (NASDAQ: BYSI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 0.3300 USD on 20 November 2026, down 83.2% over 52 weeks. Its 52-week range is 0.3164 USD to 2.440 USD: the price is 86.5% below the high and 4.3% above the low.
Its market capitalisation is 13.66M USD.
BeyondSpring reports return on equity of 3.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 501.00K USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 24 March 2027.